
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Children diagnosed with juvenile idiopathic arthritis (JIA) have triple the risk for cancer, and the findings hold for those who were never treated with biologic therapies for JIA, according to a new study.






